相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques
Jonathan T. Su et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
Dirk Schuermann et al.
LANCET HIV (2020)
Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
Solange M. Simpson et al.
PHARMACEUTICAL RESEARCH (2020)
Cabotegravir, a new option for PrEP
Tony Kirby
LANCET INFECTIOUS DISEASES (2020)
Ending the HIV Epidemic A Plan for the United States
Anthony S. Fauci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis
Fernanda P. Pons-Faudoa et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
Leah M. Johnson et al.
PHARMACEUTICS (2019)
Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
Dario Cattaneo et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir
Parul Patel et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
Stephanie E. Barrett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Treatment and prevention of HIV infection with long-acting antiretrovirals
Laura Benitez-Gutierrez et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Sustained Release Drug Delivery Applications of Polyurethanes
Michael B. Lowinger et al.
PHARMACEUTICS (2018)
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis
Corrine Ying Xuan Chua et al.
JOURNAL OF CONTROLLED RELEASE (2018)
A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence?
David Sidebottom et al.
BMC INFECTIOUS DISEASES (2018)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Long-Acting Antiretrovirals: Where Are We now?
Amesika N. Nyaku et al.
CURRENT HIV/AIDS REPORTS (2017)
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
Erica Schlesinger et al.
PHARMACEUTICAL RESEARCH (2016)
Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis
Manjula Gunawardana et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
Chasity D. Andrews et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Long-acting antiviral agents for HIV treatment
David A. Margolis et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Cabotegravir long-acting for HIV-1 prevention
Chasity D. Andrews et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Formulation and pharmacology of long-acting cabotegravir
Christine Trezza et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
Tomokazu Yoshinaga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative review
Bridget G. Haire
HIV AIDS-RESEARCH AND PALLIATIVE CARE (2015)
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
Chasity D. Andrews et al.
SCIENCE (2014)
Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
W. Spreen et al.
HIV CLINICAL TRIALS (2013)
Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
Brian A. Johns et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis
Todd J. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Contraceptive failure in the United States
James Trussell
CONTRACEPTION (2011)
A new and evolving paradigm for biocompatibitity
Jons Hilborn et al.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2007)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
